Kirbee A. Johnston

发表

A comparison of trends in opioid dispensing patterns between Medicaid pharmacy claims and prescription drug monitoring program data

Daniel M. Hartung, E. Choo, D. Hartung, 2020, Pharmacoepidemiology and drug safety.

Prescription Opioid Dispensing Patterns Prior to Heroin Overdose in a State Medicaid Program: a Case-Control Study

Daniel M. Hartung, D. Hartung, Brian Chan, 2020, Journal of General Internal Medicine.

Patterns of Prescription Opioid Use Prior to Self-reported Heroin Initiation.

P. Korthuis, D. Hartung, G. Leichtling, 2020, Journal of addiction medicine.

Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?

D. Bourdette, A. Deodhar, D. Cohen, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Identifying opioid dose reductions and discontinuation among patients with chronic opioid therapy

Daniel M. Hartung, P. Korthuis, D. Hartung, 2020, Pharmacoepidemiology and drug safety.

Qualitative study on the price of drugs for multiple sclerosis

Daniel M. Hartung, D. Bourdette, D. Hartung, 2019, Neurology.

Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis

Daniel M. Hartung, D. Bourdette, D. Hartung, 2020, Neurology.

Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study

Daniel M. Hartung, U. Ghitza, D. McCarty, 2022, Addiction Science & Clinical Practice.

Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D.

Daniel M. Hartung, Adriane N. Irwin, D. Bourdette, 2019, Health affairs.

Daniel M. Hartung, Adriane N. Irwin, D. Hartung, 2021, Drug and alcohol dependence.

Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population.

Daniel M. Hartung, Jessina C. McGregor, D. Bourdette, 2022, International journal of MS care.

Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs

Daniel M. Hartung, D. Bourdette, Chien-Wen Tseng, 2020, Neurology. Clinical practice.

Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018

Daniel M. Hartung, P. Korthuis, D. Hartung, 2019, JAMA.

Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review.

Daniel M. Hartung, Adriane N. Irwin, Sarah N. Haverly, 2018, Journal of the American Pharmacists Association : JAPhA.

Patient Outcomes Following Opioid Dose Reduction Among Patients with Chronic Opioid Therapy

Daniel M. Hartung, P. Korthuis, Sara E Hallvik, 2020 .

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin

Daniel M. Hartung, D. Bourdette, A. Deodhar, 2018, JAMA network open.

Trends and Characteristics of US Medicare Spending on Repository Corticotropin

Daniel M. Hartung, D. Bourdette, A. Deodhar, 2017, JAMA internal medicine.

Patient outcomes following opioid dose reduction among patients with chronic opioid therapy.

Daniel M. Hartung, P. Korthuis, Sara E Hallvik, 2021, Pain.

Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists.

Daniel M. Hartung, Adriane N. Irwin, Lindsey Alley, 2020, Research in social & administrative pharmacy : RSAP.

Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.

Daniel M. Hartung, Adriane N. Irwin, Lindsey Alley, 2020, Journal of the American Pharmacists Association : JAPhA.

Using prescription monitoring program data to characterize out‐of‐pocket payments for opioid prescriptions in a state Medicaid program

Daniel M. Hartung, Kun Zhang, Luke Middleton, 2017, Pharmacoepidemiology and drug safety.

Elephant in the room

Daniel M. Hartung, D. Bourdette, A. Deodhar, 2018, Annals of the rheumatic diseases.

The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.

Daniel M. Hartung, Jessina C. McGregor, D. Bourdette, 2020, Multiple sclerosis and related disorders.

Pharmacists’ Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation

Adriane N. Irwin, E. Wu, Kirbee A. Johnston, 2022, Pharmacy.

Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only.

Daniel M. Hartung, P. Korthuis, Brian Chan, 2021, Journal of substance abuse treatment.